André Jacques Scheen
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology top 0.05%
- Pharmacology and Obesity Treatment
- Cannabis and Cannabinoid Research
Papers in
-
- Diabetes Treatment and Management 298
- Diabetes Management and Research 133
- Diabetes, Cardiovascular Risks, and Lipoproteins 57
- Pharmacology 115
- Pharmacology and Obesity Treatment 102
- Co-authors
- Nicolas Paquot (59 shared papers)Nathalie Esser (16 shared papers)Luc F. Van Gaal (14 shared papers)Sylvie Legrand-Poels (4 shared papers)Pierre J. Lefèbvre (51 shared papers)Jacques Piette (2 shared papers)Olivier Ziegler (8 shared papers)Aila Rissanen (3 shared papers)
- Journals
- Diabetes & Metabolism (54 papers)Diabetes Care (21 papers)Diabetologia (19 papers)The Lancet Diabetes & Endocrinology (16 papers)The Lancet (15 papers)
- Partner nations
- BelgiumFranceUnited States
In The Last Decade
André Jacques Scheen
657 papers receiving 26.4k citations
André Jacques Scheen's Hit Papers
Peers
Comparison fields: 5 of 177
- Endocrinology, Diabetes and Metabolism 13.8k
- Pharmacology 3.9k
- Physiology 3.9k
- Endocrine and Autonomic Systems 982
- Surgery 4.9k
Countries citing papers authored by André Jacques Scheen
This map shows the geographic impact of André Jacques Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Jacques Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Jacques Scheen more than expected).
Fields of papers citing papers by André Jacques Scheen
This network shows the impact of papers produced by André Jacques Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Jacques Scheen. The network helps show where André Jacques Scheen may publish in the future.
Co-authors
The 25 scholars most cited alongside André Jacques Scheen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 698 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Hit paper breakdown → | 2005 | 3391 |
| 2 | Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes Hit paper breakdown → | 2014 | 1631 |
| 3 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2018 | 1430 |
| 4 | Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Hit paper breakdown → | 2005 | 1248 |
| 5 | Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study Hit paper breakdown → | 2006 | 600 |
| 6 | Clinical Pharmacokinetics of Metformin Hit paper breakdown → | 1996 | 547 |
| 7 | [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach]. Hit paper breakdown → | 2012 | 498 |
| 8 | 1997 | 477 | |
| 9 | Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus Hit paper breakdown → | 2014 | 470 |
| 10 | 2006 | 273 | |
| 11 | 2018 | 257 | |
| 12 | Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. | 1992 | 245 |
| 13 | 2017 | 245 | |
| 14 | 2018 | 238 | |
| 15 | 2019 | 228 | |
| 16 | 2014 | 220 | |
| 17 | Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. | 2000 | 219 |
| 18 | 2020 | 215 | |
| 19 | 2013 | 211 | |
| 20 | 2016 | 203 |
About André Jacques Scheen
André Jacques Scheen is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology, Physiology, Surgery and Cardiology and Cardiovascular Medicine, having authored 698 papers that have together received 27.8k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (298 papers), Diabetes Management and Research (133 papers), Metabolism, Diabetes, and Cancer (120 papers), Diet and metabolism studies (105 papers), Pharmacology and Obesity Treatment (102 papers), Pancreatic function and diabetes (67 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (57 papers) and Diabetes and associated disorders (31 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (13.8k citations), Pharmacology (3.9k citations), Physiology (3.9k citations), Endocrine and Autonomic Systems (982 citations) and Surgery (4.9k citations). André Jacques Scheen has collaborated with scholars based in Belgium, France and United States. Frequent co-authors include Nicolas Paquot, Nathalie Esser, Luc F. Van Gaal, Sylvie Legrand-Poels, Pierre J. Lefèbvre, Jacques Piette, Olivier Ziegler, Aila Rissanen, Stephan Rössner and Fabrice Bonnet. Their work appears in journals such as Diabetes & Metabolism, Diabetes Care, Diabetologia, The Lancet Diabetes & Endocrinology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.